ARCHIVES

ODAC Oks Carboplatin As 1st Line Ovarian Therapy; Other Drugs

This article is from The Cancer Letter archive.

Vol. 17 No. 28 | July 12, 1991

Download PDF Visit The Full Archive

Related Articles

FOCR Report Offers Recommendations, Definitions for CER

May 22, 2009

Cancer Policy; Cost Containment Impedes Research, Cancer Panel Finds

October 17, 1997

NIH Solicits Grant applications For New Type Of Small Business Award; 40 To Be Funded

September 10, 1993

B-14 Trial: No Advantage To 10 Years Of Tamoxifen

May 25, 2001

DRCCA Staff Boom To 145, Still Growing, Still Looking for People

November 25, 1983

Managed Care Plans Seek Cost Efficacy, Not Research, Center Directors Warned

March 17, 1995